Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
November 4, 2019 4:10 PM ESTConference call and webcast today at 4:30 p.m. ET
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the quarter ended September 30, 2019, and provided a corporate update.
Third Quarter 2019 and Subsequent Updates
Board Appointed Mark J. Foley as President and Chief Executive Officer (CEO). In October, Revance announced that Mark Foley had assumed the role of President and CEO,... More